TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26990892
Drug: Tandem high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandem high-dose melphalan followed by autologous transplantation (HDM/ASCT)
Study: 23519436
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 µg kg‐1
Study: 23519436
Drug: Dexmedetomidine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1.0 µg kg‐1
Study: 18387931
Drug: Rimonabant (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant (20 mg daily)
Study: 11679528
Drug: GnRH analogue
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH analogue (leuprolide acetate depot, 3.75 mg, monthly i.m. injections for 3 months)
Study: 7933233
Drug: Expectant management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectant management (no treatment)
Study: 8169405
Drug: cold‐recombinant, trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: cold‐recombinant, trivalent influenza vaccine
Study: 3127050
Drug: Deprenyl 5
Normalized name: (11C)L-deprenyl-D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deprenyl 5 mg b.i.d.
Study: 23517885
Drug: Pramipexole (0.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (0.375 mg/day titrated to 2.25 mg/day)
Study: 23517885
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pramipexole and escitalopram
Study: 21803570
Drug: Chemotherapy (CAIRO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CAIRO study)
Study: 21803570
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus targeted therapy (CAIRO2 study)
Study: 11371411
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (control; usual treatment)
Study: 25214548
Drug: Concurrent SLN/RLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent SLN/RLN injury group (n = 8)
Study: 22759326
Drug: Empirical concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical concomitant therapy (PPI, amoxicillin 1 g, clarithromycin 500 mg, metronidazole 500 mg; all drugs b.i.d.)
Study: 22759326
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy for clarithromycin-susceptible H. pylori
Study: 22759326
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy for clarithromycin-resistant strains
Study: 18555939
Drug: Aminaftone 75
Normalized name: Aminaftone
DrugBank: Aminaphthone (DB13039)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminaftone 75 mg TID for 12 weeks
Study: 12449290
Drug: Commercial antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial antioxidant supplement (dried fruit and vegetable extracts, fortified with antioxidants, gummy-type candy), taken in 2 doses per day for 21 days
Study: 12449290
Drug: Placebo, taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, taken in 2 doses per day for 21 days
Study: 10366112
Drug: High-dose D-penicillamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose D-penicillamine (750-1,000 mg/day)
Study: 10366112
Drug: Low-dose D-penicillamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose D-penicillamine (125 mg every other day)
Study: 7025719
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose cisplatin (120 mg/m2) with vindesine
Study: 7025719
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose cisplatin (60 mg/m2) with vindesine
Study: 31688572
Drug: E2 vaginal
Normalized name: Prostin E2 Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 vaginal inserts (4, 10, or 25 μg)
Study: 28903965
Drug: Enteric-coated mycophenolate
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated mycophenolate sodium (EC-MPS) plus low-dose corticosteroids
Study: 28903965
Drug: Low-dose corticosteroids
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose corticosteroids (monotherapy)
Study: 17670916
Drug: Glucose solution
Normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose solution (75 g in 300 ml water)
Study: 22240615
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg kg(‐1)
Study: 11893258
Drug: Cellophane patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellophane patch
Study: 11893258
Drug: Gentamicin ointment
Normalized name: gentamicin Ophthalmic Ointment
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gentamicin ointment seal
Study: 2220138
Drug: New trocar-cannula
Approvals — FDA: no, EMA: no, PMDA: no
Description: New trocar-cannula combination (10 French)
Study: 371561
Drug: Diflunisal (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal (250 mg b.i.d.)
Study: 26482247
Drug: Dialysate sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate sodium reduced from 138mmol/l to 136mmol/l
Study: 26482247
Drug: Dialysate sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate sodium remained at 138mmol/l
Study: 23204096
Drug: 35 percent
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 35 percent calcium-free (CF) hydrogen peroxide gel
Study: 23204096
Drug: 35 percent
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 35 percent calcium-containing (CC) hydrogen peroxide gel
Study: 11214781
Drug: Glibenclamide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (2.5 mg)
Study: 11214781
Drug: Glipizide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide (2.5 mg)
Study: 8878758
Drug: Trimethoprim/sulfamethoxazole treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim/sulfamethoxazole treatment
Study: 30933599
Drug: Weekly vouchers
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly vouchers
Study: 30933599
Drug: Monthly vouchers
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly vouchers
Study: 25857366
Drug: Silymarin 420
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin 420 mg daily in three divided doses starting 24‐48 h before cisplatin infusion and continuing through three 21‐day cisplatin chemotherapy courses
Study: 25110226
Drug: Low-glucose PD
Normalized name: calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal PD-2/2.5]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-glucose PD regimen (dextrose-based PD solution plus icodextrin and amino acids)
Study: 25110226
Drug: Conventional PD
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional PD regimen (dextrose PD solutions)
Study: 19008494
Drug: Low-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat meal (approximately 530 kcal; 100 g of carbohydrate, 1 g of fat, and 30 g of protein)
Study: 19008494
Drug: Control meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control meal (approximately 800 kcal; 100 g of carbohydrate, 31 g of fat, and 30 g of protein)
Study: 19008494
Drug: Low-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat meal plus lipid infusion (same meal as low-fat meal, total energy 800 kcal, with approximately 30 g fat via intravenous lipid infusion)
Study: 17595937
Drug: Caudal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal ketamine 0.5 mg/kg diluted with 0.9% saline
Study: 17595937
Drug: Caudal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal ketamine mixed with 0.125% bupivacaine 1 ml/kg
Study: 17595937
Drug: Plain 0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain 0.125% bupivacaine 1 ml/kg
Study: 11588451
Drug: Gastric feeding
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric feeding with erythromycin (200 mg iv every 8 hrs)
Study: 9661589
Drug: Estradiol levels
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol levels from 10-25 pg/mL
Study: 9661589
Drug: Estradiol levels
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol levels below 5 pg/mL
Study: 9661589
Drug: Estradiol levels
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol levels exceeding 5 pg/mL
Study: 8005183
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg iv infusion
Study: 8005183
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral solution
Study: 8005183
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg standard tablet
Study: 8005183
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg slow release formulation
Study: 2523957
Drug: GR 38032F,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR 38032F, 0.18 mg/kg, every six or every eight hours for three doses, beginning 30 minutes before cisplatin
Study: 596252
Drug: Intestinal sterilization
Normalized name: pork intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intestinal sterilization with systemic antibiotics
Study: 19017893
Drug: Supervised asthma
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supervised asthma therapy
Study: 16462710
Drug: Acarbose therapy
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose therapy
Study: 11455971
Drug: Regimen A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A: 12 intensive parenteral treatments of intermediate dose (1 g/m2 each) methotrexate (MTX) and mercaptopurine (MP) over 24 weeks.
Study: 11455971
Drug: Regimen B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B: 12 intensive courses of alternating myelosuppressive drug combinations over 30 weeks, including MTX/MP, teniposide (VM-26)/cytosine arabinoside (AC), and VCR/PDN/DNR/AC/ASP.
Study: 9724685
Drug: G‐6‐PD‐deficient neonates
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐6‐PD‐deficient neonates with hyperbilirubinemia
Study: 9724685
Drug: G‐6‐PD‐deficient neonates
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐6‐PD‐deficient neonates without hyperbilirubinemia
Study: 1378106
Drug: Piroximone (0.5‐mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroximone (0.5‐mg/kg bolus in 30 min and then 3‐6 micrograms/kg/min)
Study: 1378106
Drug: Enoximone (1‐mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (1‐mg/kg bolus and then 4‐20 micrograms/kg/min)
Study: 30965131
Drug: Psilocybin (315
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (315 μg/kg p.o.) during mindfulness retreat
Study: 28508427
Drug: IQP-CL-101 (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: IQP-CL-101 (two softgels twice daily before main meals)
Study: 28508427
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching placebo twice daily before main meals)
Study: 25453585
Drug: EE/GSD patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE/GSD patch (0.55 mg ethinyl estradiol and 2.1 mg gestodene)
Study: 25453585
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive (0.02 mg ethinyl estradiol and 0.1 mg levonorgestrel)
Study: 21801509
Drug: Five-element acupuncture
Normalized name: HISTA-FIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-element acupuncture treatment
Study: 19500889
Drug: Clear carbohydrate
Normalized name: Ensure Pre-Surgery Clear Carbohydrate Drink (Strawberry)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear carbohydrate drink (CCD) (400 ml, 50 g carbohydrate, 0 g protein)
Study: 19500889
Drug: Oral Nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Nutritional Supplement (ONS400) (70 g, 50 g carbohydrate, 15 g glutamine dissolved in water to a total volume of 400 ml)
Study: 19500889
Drug: Oral Nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Nutritional Supplement (ONS300) (300 ml)
Study: 17657595
Drug: Low quantities
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low quantities (2 g) of long chain lipid
Study: 17657595
Drug: Medium chain
Normalized name: Medium chain triglyceride
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium chain lipid (2 g)
Study: 17657595
Drug: Negative control
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control formulation
Study: 15118480
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg/d) and Alprazolam (1 mg/d)
Study: 9181527
Drug: Ribavirin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (1000 mg per day) and IFN-alpha (3-6 million units thrice weekly)
Study: 4039146
Drug: Carbocisteine granulate
Normalized name: carbocisteine
DrugBank: Carbocisteine (DB04339)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbocisteine granulate (750 mg)
Study: 4039146
Drug: Carbocisteine capsules
Normalized name: carbocisteine
DrugBank: Carbocisteine (DB04339)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbocisteine capsules (750 mg)
Study: 21048706
Drug: Dipeptidyl peptidase-4
Normalized name: Immature tripeptidyl-peptidase I
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dipeptidyl peptidase-4 (DPP-4) inhibitor
Study: 21048706
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of DPP-4 inhibitor and Metformin
Study: 18372687
Drug: Daily artificial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily artificial gravity (AG) countermeasure treatment
Study: 18372687
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no AG treatment)
Study: 9453690
Drug: 0.375 mg
Normalized name: vitamin A 0.375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.375 mg of sustained-release hyoscyamine twice a day
Study: 9453690
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg doxazosin QHS
Study: 9453690
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (hyoscyamine and doxazosin)
Study: 8575234
Drug: Perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4 to 8 mg once daily
Study: 8575234
Drug: Metoprolol 25
Normalized name: metoprolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 25 to 62.5 mg twice daily
Study: 31127269
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (three doses of 200 mg iron sucrose over 30 min on three separate days)
Study: 31127269
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no intravenous iron)
Study: 28939890
Drug: ELF-MF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELF-MF treatment for 45 minutes/day
Study: 28939890
Drug: ELF-MF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELF-MF treatment for 120 minutes/day
Study: 19290712
Drug: Hypothetical cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothetical cancer preventive treatment with one or two small side effects (beneficial or harmful)
Study: 11678958
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of tacrolimus after an overnight fast
Study: 11678958
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of tacrolimus 1 hour after breakfast
Study: 11678958
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of tacrolimus after an overnight fast and 0.5 hours after breakfast (in 4 patients)
Study: 9660327
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ethanol (LD)
Study: 9660327
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose ethanol (HD)
Study: 29886915
Drug: Low-dose naloxone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose naloxone infusion (0.5 μg/kg/h)
Study: 29886915
Drug: High-dose naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose naloxone infusion (2.5 μg/kg/h)
Study: 26364275
Drug: Huperzine A
Normalized name: Huperzine A
DrugBank: Huperzine A (DB04864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huperzine A (0.4 mg)
Study: 26364275
Drug: Huperzine A
Normalized name: Huperzine A
DrugBank: Huperzine A (DB04864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huperzine A (0.8 mg)
Study: 24159353
Drug: Pomegranate extract
Normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate extract (2g per day in 2 POMx pills)
Study: 24159353
Drug: Placebo (pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (pills containing no pomegranate ingredients)
Study: 12564608
Drug: Placebo (pressurized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (pressurized metered-dose inhaler)
Study: 1888248
Drug: Diltiazem (sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (sustained release) 60 to 180 mg twice a day
Study: 1888248
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 to 100 mg once a day
Study: 1888248
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 to 20 mg once a day
Study: 21122063
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three treatments
Study: 28880931
Drug: Cardiac output
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac output goal directed therapy (GDT) algorithm
Study: 25471599
Drug: WHEY (whey
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHEY (whey protein solution)
Study: 25471599
Drug: GEL (leucine-enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEL (leucine-enriched whey protein gel)
Study: 21823549
Drug: OM‐ER 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM‐ER 15 mg
Study: 21823549
Drug: OM‐ER 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM‐ER 30 mg
Study: 21823549
Drug: OC‐CR 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC‐CR 30 mg
Study: 21823549
Drug: OC‐CR 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC‐CR 60 mg
Study: 17181373
Drug: Rifamycin-based antituberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifamycin-based antituberculosis therapy
Study: 17181373
Drug: Timing of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timing of HAART initiation after antituberculosis therapy
Study: 2112165
Drug: Topical therapy
Normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical therapy with 2% mupirocin
Study: 6416510
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (insulin A)
Study: 6416510
Drug: Porcine insulin
Normalized name: Porcine insulin
DrugBank: Insulin pork (DB00071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine insulin (insulin B)
Study: 31216051
Drug: Repaglinide and
Normalized name: metformin and repaglinide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide and aspirin (without clopidogrel use)
Study: 27240549
Drug: Cefuroxime administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime administered to mothers 15-60 minutes before Caesarean section
Study: 16163743
Drug: Intervention by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention by mental health professional for treatment of depression
Study: 12415443
Drug: Hypertonic saline/dextran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline/dextran solution (HSS group, n=13)
Study: 9915292
Drug: Amino acid-based
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid-based dialysis solution
Study: 7587846
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (multiple daily injections of insulin and glipizide)
Study: 7587846
Drug: Standard insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard insulin treatment (one morning injection per day)
Study: 7587846
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (stepped approach to insulin therapy)
Study: 2341068
Drug: Ceftriaxone (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (single daily dose)
Study: 2341068
Drug: Cefazolin and
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin and Gentamicin (combined therapy every 8 hours)
Study: 7017488
Drug: Broncaspin (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broncaspin (1.2 g suppositories, twice a day for 14 days)
Study: 7017488
Drug: Dimethylaminophenazone guaiacolglycolate
Normalized name: Dimethylaminophenazon
DrugBank: Aminophenazone (DB01424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethylaminophenazone guaiacolglycolate (commercial form, twice a day for 14 days)
Study: 31094806
Drug: Meloxicam IV
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meloxicam IV (5-60 mg)
Study: 27882910
Drug: Wii-therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wii-therapy
Study: 24917588
Drug: Daily muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily muscle manual stretching, passive articular mobilization, and palmar splint (Group B)